{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T18:15:01Z","timestamp":1780424101180,"version":"3.54.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.critrevonc.2024.104408","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:18:45Z","timestamp":1718421525000},"page":"104408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors"],"prefix":"10.1016","volume":"201","author":[{"given":"Francesca R.","family":"Mauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Frustaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Oltolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Zappulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104408_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"1128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104408_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"10102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in real life: focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104408_bib6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"22134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104408_bib7","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104408_bib8","first-page":"492","article-title":"A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies","volume":"3","author":"Sharman","year":"2022","journal-title":"E J. Haem"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104408_bib9","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjh.16345","article-title":"Practical management of tumor lysis syndrome in venetoclax- treated patients with chronic lymphocytic leukemia","volume":"188","author":"Gribben","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104408_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104408_bib11","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104408_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594556","article-title":"Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia","volume":"11","author":"Griggio","year":"2020","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104408_bib13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1517\/14656566.9.9.1481","article-title":"Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice","volume":"9","author":"Dasanu","year":"2008","journal-title":"Expert Opin. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104408_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","author":"Williams","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104408_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104408_bib17","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3390\/cancers13133240","article-title":"Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"13","author":"Mauro","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104408_bib18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib19","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/ajh.27093","article-title":"The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: a study by ERIC, the European research initiative on CLL","volume":"98","author":"Visentin","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104408_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2020006854","article-title":"Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report","volume":"136","author":"Cuneo","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib21","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/hon.2899","article-title":"Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report","volume":"39","author":"Cuneo","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/10428194.2022.2053532","article-title":"How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia","volume":"63","author":"Deodato","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/hon.3092","article-title":"SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: the Italian Hematology Alliance on COVID-19 cohort","volume":"41","author":"Merli","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104408_bib25","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104408_bib26","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hon.2814","article-title":"Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients","volume":"39","author":"Cassin","year":"2021","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib28","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104408_bib29","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1074\/jbc.M115.687251","article-title":"Analysis of the effects Of the Bruton's tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fc\u03b3 receptor (Fc\u03b3R) function","volume":"291","author":"Ren","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"Oncoimmunology"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104408_bib31","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104408_bib32","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104408_bib33","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2024.104408_bib34","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2019-125617","article-title":"Ibrutinib Treatment mitigates phenotypic alterations of non-neoplastic immune cell compartments in chronic lymphocytic leukemia","volume":"134","author":"Griggio","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104408_bib35","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of Patients with CLL is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104408_bib36","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104408_bib37","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","article-title":"Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study","volume":"7","author":"Moreno","year":"2023","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104408_bib38","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104408_bib39","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"NEJM"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104408_bib40","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104408_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/cancers14010207","article-title":"Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia: results of the gimema LLC1114 Study","volume":"14","author":"Mauro","year":"2021","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104408_bib43","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib44","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104408_bib45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104408_bib46","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/bjh.17994","article-title":"Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study","volume":"196","author":"Cull","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104408_bib48","doi-asserted-by":"crossref","unstructured":"Munir T., Shadman M.; Robak T., Brown J.R., Kahl B., Ghia P., et al. Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): extended follow-up of the SEQUOIA study. EHA 2023; Abstract number: P639.","DOI":"10.1097\/01.HS9.0000969460.15364.af"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib49","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood.2020008164","article-title":"A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial","volume":"137","author":"Michallet","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104408_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"NEJM"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib51","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"25","key":"10.1016\/j.critrevonc.2024.104408_bib52","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib Versus Investigator's Choice in Relapsed\/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"31","key":"10.1016\/j.critrevonc.2024.104408_bib54","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104408_bib56","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III Trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"NEJM"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104408_bib59","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"NEJM"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104408_bib60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104408_bib61","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib62","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3324\/haematol.2022.282116","volume":"108","author":"Mauro","year":"2023","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104408_bib63","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"NEJM"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104408_bib64","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"NEJM"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib65","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia a non-randomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2024.104408_bib66","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease Cohort of the randomized phase II captivate study","volume":"39","author":"Wierda","year":"2021","journal-title":"JCO"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104408_bib67","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104408_bib68","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104408_bib69","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib70","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"National cancer research institute chronic lymphocytic leukemia subgroup. Chronic lymphdoi: 10.1056\/NEJMoa2310063ocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"NEJM"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104408_bib71","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104408_bib72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104408_bib73","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2024.104408_bib74","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"NEJM"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.critrevonc.2024.104408_bib76","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104408_bib77","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood.2020008608","article-title":"Venetoclax and ibrutinib for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"137","author":"Niemann","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104408_bib78","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S1470-2045(22)00220-0","article-title":"Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141\/VISION): primary analysis of an open- label, randomised, phase 2 trial","volume":"23","author":"Kater","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104408_fur1","article-title":"Prevention and management of infectious complications in patients with chronic leucocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines","volume":"1","author":"Mikulska","year":"2024","journal-title":"Blood Rev."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:23:13Z","timestamp":1723634593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":79,"alternative-id":["S1040842824001513"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104408","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104408"}}